Bright Minds Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ian McDonald

Chief executive officer

CA$626.2k

Total compensation

CEO salary percentage	n/a
CEO tenure	5yrs
CEO ownership	21.8%
Management average tenure	2yrs
Board average tenure	2yrs

Recent management updates

Recent updates

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04

CEO

Ian McDonald (34 yo)

5yrs

Tenure

CA$626,178

Compensation

Mr. Ian McDonald is Co-Founder of Bright Minds Biosciences Inc. and serves as its Chief Executive Officer since June 06, 2020 and serves as its President and Director since May 31, 2019. He served as Presi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ian McDonald	Co-Founder	5yrs	CA$626.18k	21.84% CA$ 1.3m
Ryan E. S. Cheung	Chief Financial Officer	4yrs	CA$120.00k	0% CA$ 0
Jan Pedersen	Chief Science Officer & Director	1.7yrs	CA$799.72k	0% CA$ 0
Mark Smith	Chief Medical Officer	1.4yrs	CA$505.51k	no data
Emer Leahy	Consultant	2yrs	no data	no data

2.0yrs

Average Tenure

56yo

Average Age

Experienced Management: DRUG's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ian McDonald	Co-Founder	5yrs	CA$626.18k	21.84% CA$ 1.3m
Jan Pedersen	Chief Science Officer & Director	2.1yrs	CA$799.72k	0% CA$ 0
Robert Malenka	Member of Scientific Advisory Board	2yrs	no data	no data
Herbert Meltzer	Member of Scientific Advisory Board	2yrs	no data	no data
David Weiner	Independent Non-Executive Director	1.3yrs	CA$22.04k	0% CA$ 0
Jeremy Fryzuk	Independent Director	3.7yrs	CA$7.69k	0.054% CA$ 3.3k
Nils Bottler	Independent Director	3.7yrs	CA$7.69k	0.090% CA$ 5.5k
Michael Bogenschutz	Member of Scientific Advisory Board	2yrs	no data	no data
Peter Hendricks	Member of Scientific Advisory Board	2yrs	no data	no data

2.0yrs

Average Tenure

38yo

Average Age

Experienced Board: DRUG's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Bright Minds Biosciences Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new and inexperienced directors

Bright Minds Biosciences Inc., Annual General Meeting, Mar 22, 2024

Less than half of directors are independent

Less than half of directors are independent

Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director

Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee

Recent updates

High number of new and inexperienced directors

Bright Minds Biosciences Inc., Annual General Meeting, Mar 22, 2024

Less than half of directors are independent

Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding

New major risk - Market cap size

Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101

Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101

Less than half of directors are independent

Bright Minds Goes for 5:1 Shares Consolidation, Hopes to Regain Nasdaq Compliance

Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee

Bright Minds Biosciences Inc., Annual General Meeting, Mar 24, 2023

Bright Minds Biosciences Inc. Announces the Resignation of Doug Williamson from Board of Directors

Bright Minds Biosciences Inc. announced that it expects to receive CAD 2.05 million in funding

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer, Effective December 1, 2022

High number of new and inexperienced directors

Bright Minds Biosciences Announces Executive Changes

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Bright Minds Biosciences Announces Changes to Its Executive Leadership Team

High number of new and inexperienced directors

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Bright Minds Biosciences Provides Scientific Update on Its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

High number of new and inexperienced directors

Bright Minds Biosciences Inc. Provides Scientific Update

CEO & Director recently bought CA$116k worth of stock

Bright Minds Biosciences Inc., Annual General Meeting, May 18, 2021

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 25.00371 million.

Bright Minds Biosciences Inc. Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

Bright Minds Biosciences Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

Bright Minds Biosciences Announces Scientific Advisory Team Appointment

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age